Table 3.
Placebo Population: Baseline Characteristics by In‐Trial Systolic Blood Pressure Mean Tertiles
| SBP | P Value | |||
|---|---|---|---|---|
| ≤117 mm Hg (N=984) | >117 and ≤128.7 mm Hg (N=974) | >128.7 mm Hg (N=977) | ||
| Age (y), mean (SD) | 58.1 (12.3) | 60.5 (11.0) | 61.9 (10.8) | <0.001 |
| Male (%) | 764 (77.6) | 766 (78.6) | 730 (74.7) | 0.101 |
| Caucasian vs non‐Caucasian (%) | 805 (81.8) | 872 (89.5) | 907 (92.8) | <0.001 |
| Current smokers (%) | 168 (17.1) | 179 (18.4) | 163 (16.7) | 0.586 |
| Body mass index (kg/m2), mean (SD) | 26.5 (4.7) | 27.8 (4.6) | 29.4 (5.2) | <0.001 |
| Resting heart rate (bpm), mean (SD) | 80.9 (10.7) | 79.6 (9.0) | 79.2 (8.8) | <0.001 |
| Systolic blood pressure (mm Hg), mean (SD) | 108.8 (11.9) | 121.3 (11.2) | 133.6 (13.0) | <0.001 |
| Diastolic blood pressure (mm Hg), mean (SD) | 70.1 (8.4) | 76.0 (8.0) | 80.7 (8.5) | <0.001 |
| LVEF (%), mean (SD) | 27.6 (5.4) | 29.2 (5.2) | 30.1 (4.5) | <0.001 |
| eGFR (mL/min per 1.73 m2), mean (SD) | 76.8 (25.1) | 75.3 (21.9) | 73.9 (21.4) | 0.024 |
| Serum creatinine (μmol/L), mean (SD) | 95.7 (25.4) | 96.1 (25.9) | 96.4 (26.5) | 0.847 |
| Hemoglobin (g/L), mean (SD) | 140.9 (14.9) | 141.7 (14.4) | 143.9 (15.4) | <0.001 |
| NYHA Class III/IV vs Class II (%) | 529 (53.8) | 494 (50.7) | 473 (48.5) | 0.063 |
| Ischemic heart failure (%) | 602 (61.2) | 675 (69.3) | 690 (70.6) | <0.001 |
| History of MI (%) | 529 (53.8) | 567 (58.2) | 538 (55.1) | 0.125 |
| History of hypertension (%) | 430 (43.7) | 657 (67.5) | 824 (84.3) | <0.001 |
| History of diabetes (%) | 236 (24.0) | 315 (32.3) | 352 (36.0) | <0.001 |
| History of stroke (%) | 81 (8.2) | 94 (9.7) | 88 (9.0) | 0.545 |
| History of COPD (%) | 107 (10.9) | 104 (10.7) | 109 (11.2) | 0.943 |
| Coronary artery disease (%) | 638 (64.8) | 719 (73.8) | 757 (77.5) | <0.001 |
| Beta‐blocker at randomization (%) | 872 (88.6) | 873 (89.6) | 890 (91.1) | 0.191 |
| Beta‐blocker dose: no BB (%) | 112 (11.5) | 101 (10.5) | 87 (9.1) | <0.001 |
| Beta‐blocker dose: <25% (%) | 171 (17.5) | 120 (12.5) | 90 (9.4) | |
| Beta‐blocker dose: 25%; 50% (%) | 282 (28.9) | 233 (24.3) | 238 (24.9) | |
| Beta‐blocker dose: 50%; 100% (%) | 239 (24.5) | 261 (27.2) | 273 (28.6) | |
| Beta‐blocker dose: ≥100% (%) | 171 (17.5) | 245 (25.5) | 266 (27.9) | |
| Selective beta‐blocker at randomization (%) | 431 (43.8) | 492 (50.5) | 552 (56.5) | <0.001 |
| Beta‐2 agonists at randomization (%) | 27 (2.7) | 29 (3.0) | 31 (3.2) | 0.854 |
| Drugs for obstructive airway disease at randomization (%) | 89 (9.0) | 83 (8.5) | 86 (8.8) | 0.920 |
| Adrenergics, inhalants at randomization (%) | 53 (5.4) | 53 (5.4) | 49 (5.0) | 0.900 |
| Adrenergics and other drugs for obstructive airway disease at rand (%) | 33 (3.4) | 32 (3.3) | 25 (2.6) | 0.528 |
| ACE inhibitor at randomization (%) | 736 (74.8) | 764 (78.4) | 793 (81.2) | 0.003 |
| Diuretic at randomization (%) | 831 (84.5) | 781 (80.2) | 799 (81.8) | 0.045 |
| ARB at randomization (%) | 142 (14.4) | 137 (14.1) | 143 (14.6) | 0.936 |
| Calcium‐channel blocker at randomization (%) | 30 (3.0) | 59 (6.1) | 141 (14.4) | <0.001 |
| Antialdosterone at randomization (%) | 703 (71.4) | 607 (62.3) | 434 (44.4) | <0.001 |
| Device (%) | 71 (7.2) | 28 (2.9) | 19 (1.9) | <0.001 |
ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BB, beta blocker; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association.